In agreement with the results obtained in healthy donors, silibinin appeared to have immunosuppressive/anti-inflammatory effects on T lymphocytes from RA patients inducing apoptosis, inhibiting proliferation and both IL-17 and TNF-α expression, thus assigning to this molecule a potential value as therapeutic tool in this disease. This evidence concerns the gene IL17A and rheumatoid arthritis.